Prescriber Scope of Practice for Anxiety in North Carolina

If you’re a psychiatrist or psychiatric nurse practitioner treating anxiety disorders via telehealth, you’re navigating one of the most complex regulatory landscapes in medicine right now. Federal controlled substance rules, state-by-state telehealth laws, varying scope of practice regulations, and mandatory prescription monitoring — all while trying to actually help anxious patients get relief.

Here’s what you need to know to stay compliant, avoid Board scrutiny, and practice confidently across state lines in 2026.

The Federal Picture: DEA Extends Telehealth Flexibility Through 2025 (For Now)

The good news first: You can still prescribe controlled anxiety medications via telehealth without an initial in-person visit — but this is temporary, and the clock is ticking.

The DEA extended COVID-era telehealth prescribing flexibilities through December 31, 2025, marking the third extension of these policies. This means through the end of 2025, DEA-registered practitioners can prescribe Schedule II–V controlled substances (including benzodiazepines commonly used for acute anxiety) via telemedicine to new patients without requiring an in-person exam first.

What this means practically: A psychiatrist can conduct a video evaluation of a patient with panic disorder and prescribe clonazepam that same day. A PMHNP treating generalized anxiety can initiate alprazolam after a telehealth assessment. This access has been critical — many anxiety patients prefer (or can only access) virtual care.

But here’s the catch: This is still governed by temporary public health emergency waivers, not permanent law. The Ryan Haight Act — the federal law that normally requires an in-person medical evaluation before prescribing controlled substances ‘by means of the Internet’ — remains on the books. The DEA’s current position is a temporary exception during the declared emergency period.

What’s Coming: The DEA’s Uncertain Path Forward

In early 2023, the DEA proposed new rules that would have reinstated an in-person visit requirement for ongoing controlled substance prescribing via telehealth (with only a limited 30-day supply allowable without seeing the patient). The mental health community responded with over 38,000 public comments, many expressing concern that this would devastate access to psychiatric care.

The DEA pulled back, postponed the rule, and committed to developing a ‘new path forward for telemedicine.’ As of February 2026, we’re still waiting for that final rule.

What to expect: Most experts anticipate some middle ground — possibly requiring an in-person exam within a certain timeframe (30-90 days) for ongoing controlled prescribing, or creating a special DEA telemedicine registration that allows remote prescribing under specific conditions. The DEA was actually directed by Congress to create this special registration years ago, but it’s never been implemented.

Action item for providers: Don’t build your entire practice model around indefinite telehealth-only controlled prescribing. Have a Plan B — whether that’s affiliate clinic relationships for in-person visits, hybrid care models, or limiting your telehealth practice to non-controlled medications (SSRIs, SNRIs, buspirone, hydroxyzine) that aren’t subject to Ryan Haight restrictions.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrists vs. PMHNPs: Scope of Practice Differences That Matter

Psychiatrists: Full Authority, But Still State-Licensed

As a psychiatrist (MD or DO), your scope is straightforward: you can do everything — diagnose any anxiety disorder, provide therapy, prescribe any medication from beta-blockers to benzodiazepines to off-label antipsychotics for treatment-resistant anxiety. You have full independent practice authority in every state.

The regulatory challenges aren’t about scope — they’re about multi-state licensing and prescribing compliance:

Licensing: You must hold a valid medical license in each state where your patients are located. Texas, Illinois, Pennsylvania, and Florida are Interstate Medical Licensure Compact (IMLC) states, which can streamline getting additional licenses if you’re already licensed in another compact state. California and New York are not in the IMLC — you go through the full conventional process there.

Prescribing requirements:

• You need a DEA registration (and many states require a separate state controlled substance license — Illinois and Florida, for example)
• You must comply with state Prescription Drug Monitoring Program (PDMP) requirements
• Most states now mandate or strongly encourage e-prescribing for controlled substances

The PDMP requirements are where many psychiatrists trip up. New York’s I-STOP law requires you to check the state PMP registry before EVERY prescription for Schedule II, III, or IV substances — including every benzodiazepine refill. Pennsylvania requires checking before each new prescription of opioids or benzodiazepines. Florida mandates a check before any controlled prescription and every 90 days for ongoing therapy.

Missing these checks isn’t just bad practice — state medical boards actively audit for PDMP compliance, and violations can trigger disciplinary action.

PMHNPs: Capable Providers in a Patchwork of State Rules

Psychiatric Mental Health Nurse Practitioners are fully trained to assess, diagnose, and manage anxiety disorders, including medication management. Every state allows PMHNPs to treat anxiety and prescribe medications for it.

But state scope of practice laws vary dramatically, creating a complex landscape for telehealth practice:

Independent Practice States (Full Authority)

Illinois and New York allow experienced PMHNPs to practice without physician oversight:

• New York: After 3,600 hours of practice under a collaborative agreement, NPs gain full practice authority — no supervising physician needed (law made permanent in 2022)
• Illinois: NPs with 4,000+ clinical hours and additional training can apply for Full Practice Authority, allowing independent practice and prescribing

California is in transition: AB 890 created a pathway to NP independence starting in 2023 for certain practice settings, with full independence across all settings opening up in 2026 for qualified NPs.

In these states, an experienced PMHNP can evaluate anxiety patients via telehealth, make independent treatment decisions, and prescribe medications (including controlled substances) under their own authority.

Restricted Practice States (Physician Collaboration Required)

Texas, Florida, and Pennsylvania require PMHNPs to work under physician supervision or collaborative agreements:

• Texas: NPs must have a Prescriptive Authority Agreement (PAA) with a physician; one physician can supervise up to 7 NPs
• Pennsylvania: Requires a collaborative agreement; physician doesn’t need to be on-site but must provide oversight
• Florida: NPs must practice under a supervisory protocol with a physician; notably, Florida’s 2020 NP independence law excluded psychiatric specialists

For telehealth platforms, this means ensuring physician collaborators are available in these states so PMHNPs can legally prescribe.

The Controlled Substance Wild Card

Even in states where NPs have prescriptive authority, controlled substance prescribing often has special restrictions:

Schedule II limitations (relevant if treating comorbid ADHD or using certain sedatives):

• Texas explicitly prohibits APRNs from prescribing Schedule II controlled substances in outpatient settings except in hospital-based practice or hospice/palliative care
• Florida limits NP Schedule II prescriptions to 7-day supplies unless the NP is a certified ‘psychiatric nurse’ treating mental health conditions (PMHNPs get an exemption)

Schedule IV benzodiazepines (the medications most relevant to anxiety):

• Most states permit NP prescribing of Schedule IV drugs like alprazolam, lorazepam, clonazepam
• Pennsylvania allows up to 90-day supply per prescription for Schedule IV
• New York allows experienced independent NPs to prescribe these under their own authority
• All states require NPs to have DEA registration and comply with PDMP requirements

Bottom line for PMHNPs: You can absolutely manage anxiety medication virtually, but you must know which state’s rules you’re operating under at any given moment. A PMHNP licensed in both Texas and California needs to remember that in Texas, they can’t touch Schedule II medications for outpatient anxiety comorbidities, while in California (by 2026, if they qualify for independence), they could.

State-by-State Telehealth Prescribing Rules: The Details That Matter

California: Telehealth-Friendly With Strict Monitoring

What you can do: Prescribe anxiety medications (including controlled substances) via telehealth without a prior in-person exam, as long as you conduct an ‘appropriate examination’ that meets standard of care — which can be done via video, phone, or even asynchronous methods if clinically appropriate.

Requirements:

• Must hold California medical license (no special telehealth license; not in IMLC)
• Mandatory e-prescribing for all medications (since 2022)
• CURES PDMP check required before prescribing Schedule II–IV drugs and at least every 4 months for ongoing therapy
• NPs moving to full independence by 2026 under AB 890

The economics: California is a high-demand market with strong telehealth adoption and excellent insurance reimbursement. But getting licensed takes time and isn’t expedited.

Texas: Modern Telehealth Framework With Pain Management Carve-Outs

What you can do: Establish patient relationships via synchronous audio-visual telehealth and prescribe anxiety medications, including controlled substances.

What you can’t do: Use telehealth to prescribe Schedule II controlled substances for chronic pain management (doesn’t apply to psychiatric treatment).

Requirements:

• Texas medical license or IMLC pathway (TX joined in 2021)
• Real-time video required for initial evaluations
• Mandatory PDMP check for opioids, benzodiazepines, barbiturates, and carisoprodol before prescribing
• NPs restricted: cannot prescribe Schedule II outside hospital/hospice; require physician supervision

The reality: Texas removed its old in-person requirement in 2017 (SB 1107), making it one of the more forward-thinking states for tele-mental health. The chronic pain prohibition doesn’t touch psychiatric benzodiazepine prescribing.

Florida: Explicit Psychiatric Exemption for Controlled Substances

What makes Florida unique: State law prohibits Schedule II controlled substance prescribing via telehealth except for four specific situations, including treatment of psychiatric disorders.

This means a Florida psychiatrist or psychiatric NP can prescribe Schedule II stimulants for ADHD or other psychiatric Schedule II medications via telehealth, while a physician treating chronic pain cannot prescribe Schedule II opioids remotely.

Requirements:

• Florida license OR special Telehealth Provider Registration for out-of-state clinicians (one of the few states offering this)
• Written patient consent for telehealth treatment
• E-FORCSE PDMP check before any controlled prescription and every 90 days thereafter
• Mandatory e-prescribing for controlled substances
• NPs need physician protocol (psychiatric NPs not included in FL’s autonomous NP category)

The opportunity: Florida’s telehealth registration allows out-of-state providers to practice in Florida without obtaining a full state license — over 1,200 providers have used this pathway. For a psychiatrist already licensed in another state, this is a relatively quick way to expand your patient base.

New York: Strong PDMP Requirements, NP Independence for Experienced Providers

What you can do: Conduct telehealth evaluations and prescribe controlled substances (under current federal waivers) without state-imposed restrictions beyond standard of care.

Requirements:

• I-STOP/PMP mandatory: Check the prescription monitoring database before every Schedule II, III, or IV prescription — yes, every single benzodiazepine refill
• Mandatory e-prescribing for all medications (since 2016)
• Experienced NPs (3,600+ hours) have full practice authority since 2022

The administrative reality: New York’s I-STOP requirement is more frequent than most states. Many EHRs now integrate automatic PMP queries to streamline this, but if you’re writing benzos for anxiety patients, build this check into your workflow every time.

Pennsylvania: Collaborative Agreements and Per-Prescription PDMP Checks

What you can do: Provide telehealth evaluations and prescribe anxiety medications if you meet standard of care (typically requiring real-time audio-visual for new patients).

Requirements:

• PDMP check required before initial prescription of any opioid or benzodiazepine and for each subsequent prescription (interpreted as every refill)
• E-prescribing mandatory for controlled substances (since 2019)
• NPs must have collaborative agreement; can prescribe Schedule II up to 30-day supply, Schedule IV up to 90-day supply
• IMLC member for physicians (joined 2017)

The compliance note: Pennsylvania specifically named benzodiazepines in its PDMP requirement due to their abuse potential and interaction with opioids. If you’re prescribing alprazolam for panic disorder, you’re checking the PDMP every time you refill it.

Illinois: Full NP Practice Authority With Audio-Only Flexibility

What you can do: Conduct telehealth evaluations (even audio-only for mental health services when necessary) and prescribe anxiety medications.

Requirements:

• Illinois Prescription Monitoring Program registration and consultation required for Schedule II prescriptions
• State controlled substance license required in addition to DEA registration
• NPs with Full Practice Authority can prescribe independently after 4,000 hours; still need physician consult relationship for Schedule II opioids during first 5 years of FPA
• IMLC member for physicians; joined Nurse Licensure Compact for RNs in 2022

The telehealth advantage: Illinois explicitly permits audio-only telehealth for behavioral health services (made permanent in 2021’s HB 3308), recognizing that some anxious patients may not have video access. However, be cautious with controlled prescribing via audio-only — federal DEA rules may constrain this post-2025.

The Economics of Telehealth Anxiety Treatment: Why Platforms Beat DIY

Here’s the uncomfortable truth about building an independent telehealth anxiety practice: patient acquisition is brutally expensive and slow when you’re starting from scratch.

The Real Cost of DIY Patient Acquisition

Let’s be honest about the economics:

SEO takes 6-12 months of consistent investment before generating meaningful patient flow. You’re paying for content creation, technical optimization, and competing against established practices and platforms. Most solo providers don’t have the expertise or patience for this.

Google Ads for mental health keywords run $15-40+ per click, and most clicks don’t convert to booked patients. A realistic cost per booked patient through PPC is $200-400+ when you factor in:

• Ad spend testing and optimization
• Agency or consultant fees if you’re not doing it yourself
• Staff time to handle and qualify leads
• No-show rates from cold leads who aren’t truly committed
• Months of campaign refinement to get conversion rates up

Directory listings (Psychology Today, Zocdoc) charge monthly subscription fees AND you’re competing with hundreds of other providers on the same page. Zocdoc charges per booking ($35-100+ depending on specialty) but the monthly subscription cost adds up quickly.

When you factor in ALL costs — agency fees, ad spend, staff time, no-shows, failed campaigns, and months of investment before results — acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+ per patient.

For most providers, especially those starting out or looking to scale, that’s a significant barrier. You’re gambling thousands per month on marketing channels with uncertain ROI.

Why Platforms Like Klarity Make Economic Sense

Klarity Health uses a pay-per-appointment model where providers pay a standard listing fee per new patient lead. Here’s why that economic model works:

No upfront marketing spend: You’re not investing $3,000-5,000/month in advertising with uncertain results. Zero spend until you actually see patients.

Pre-qualified patients: Patients are already matched to your specialty (anxiety treatment) and availability. They’re not cold clicks from a Google ad — they’re people who’ve already indicated they want psychiatric care.

No wasted ad spend: You’re not paying for clicks that don’t convert, SEO investments that take months to pay off, or directory listings where you get lost in the crowd.

Built-in infrastructure: Telehealth platform, EHR, billing, credentialing support — no separate platform costs or staff overhead to get started.

Both insurance and cash-pay flow: Access to patients across payment types without having to build separate marketing funnels.

You control your schedule: Only pay when you see patients. Want to scale up? Accept more appointments. Need to pull back? Adjust your availability.

Frame it this way: Instead of spending $3,000-5,000/month on marketing with uncertain results and 6+ months before seeing ROI, you pay only when a qualified patient books with you. That’s guaranteed ROI versus gambling on marketing channels you may not understand.

For an established psychiatrist with a full practice and marketing expertise, DIY can eventually be cost-effective. But for most providers — especially PMHNPs starting out, psychiatrists adding telehealth, or anyone looking to expand across states without massive overhead — platforms that handle patient acquisition remove all the risk.

What to Do Right Now: Practical Compliance Steps

For all providers treating anxiety via telehealth:

1. Know your state PDMP requirements and integrate them into your workflow (most EHRs can automate queries)
2. Use e-prescribing systems with two-factor authentication for controlled substances
3. Document thoroughly — note that visits were conducted via telehealth, document informed consent, maintain records equivalent to in-person care
4. Stay current on DEA rule proposals — subscribe to DEA updates or professional organization alerts so you’re not caught off-guard when final rules drop
5. Have a hybrid care plan — know where you can refer patients for in-person visits if needed, whether that’s affiliate clinics or local providers

For multi-state practice:

1. Get your licensing in order first — use IMLC if you qualify, budget time for California and New York applications
2. Understand scope limitations for each state if you’re a PMHNP (maintain a quick-reference chart of what you can prescribe where)
3. Ensure you have physician collaborators in restricted states if needed
4. Register for state PDMPs in every state you practice (this often requires separate registration beyond DEA)

For joining a telehealth platform:

1. Verify they handle compliance infrastructure — credentialing, PDMP integration, state-specific workflows
2. Understand the economics — what’s the per-appointment fee structure vs. building your own practice
3. Check if they provide malpractice coverage or require you to carry your own
4. Confirm they have patient flow in the states where you’re licensed

The Bottom Line

Treating anxiety disorders via telehealth in 2026 is clinically effective, economically viable, and legally permissible — but it requires navigating a complex regulatory landscape that varies by state, provider type, and medication class.

The federal DEA framework is in flux. State rules on PMHNP scope vary wildly. PDMP requirements differ everywhere. Multi-state licensing takes time and money.

But here’s what’s universal: there’s enormous unmet need for anxiety treatment, telehealth removes barriers for patients, and platforms that handle the administrative complexity let you focus on what you’re trained to do — actually helping people get better.

If you’re a psychiatrist or PMHNP looking to expand your anxiety treatment practice via telehealth, joining a platform like Klarity means you get instant access to pre-qualified patients across multiple states, with none of the upfront marketing risk or administrative burden of building from scratch.

Ready to treat more anxiety patients without the overhead? Explore joining Klarity’s provider network and start seeing patients this month.

Frequently Asked Questions

Can I prescribe benzodiazepines via telehealth in 2026?

Yes, under current federal DEA waivers (extended through December 31, 2025), you can prescribe Schedule IV benzodiazepines like alprazolam, clonazepam, or lorazepam via telehealth to new patients without requiring an initial in-person visit. However, this is temporary — the DEA is developing final rules that may reinstate in-person requirements in the future. State laws also apply: you must have a license in the patient’s state, comply with PDMP requirements, and meet state telehealth standards.

What’s the difference between a psychiatrist and PMHNP for anxiety treatment scope?

Psychiatrists (MD/DO) have full independent practice authority in all states — they can diagnose, prescribe any medication including controlled substances, and provide therapy without supervision. PMHNPs are fully trained to treat anxiety but face state-by-state scope variations: some states (NY, IL, CA by 2026) allow experienced NPs full independence, while others (TX, FL, PA) require physician collaboration agreements. Controlled substance prescribing by NPs may also have additional state restrictions (e.g., Texas NPs cannot prescribe Schedule II in outpatient settings).

Do I need separate licenses for each state I practice telehealth in?

Yes. You must hold a valid medical license (or APRN license for NPs) in every state where your patients are physically located during the telehealth visit. The Interstate Medical Licensure Compact (IMLC) can streamline this for physicians in member states (TX, IL, PA, FL are members; CA and NY are not). Florida offers a special Telehealth Provider Registration for out-of-state clinicians. Some states have Nurse Licensure Compacts, but APRN practice authority still typically requires state-specific authorization.

What PDMP requirements apply to anxiety medication prescribing?

This varies by state. New York requires checking the prescription monitoring database before every Schedule II-IV prescription (including every benzodiazepine refill). Pennsylvania requires checks before each opioid or benzodiazepine prescription. Florida mandates checks before any controlled prescription and every 90 days for ongoing therapy. California requires checking within 24 hours of initially prescribing Schedule II-IV and every 4 months thereafter. Illinois requires registration and consultation for Schedule II prescriptions. Failing to comply with state PDMP laws can result in disciplinary action.

Can PMHNPs prescribe anxiety medications independently?

It depends on the state. In New York (after 3,600 practice hours), Illinois (with Full Practice Authority after 4,000 hours), and California (by 2026 for qualified NPs), experienced PMHNPs can practice and prescribe independently. In Texas, Florida, and Pennsylvania, PMHNPs require physician collaborative agreements or supervision. Even in independent practice states, NPs must comply with controlled substance prescribing rules, obtain DEA registration, and follow PDMP requirements just like physicians.

What happens if the DEA changes telehealth prescribing rules?

The current temporary waivers allowing telehealth prescribing of controlled substances without in-person visits expire December 31, 2025. The DEA is developing final rules for a ‘new path forward’ but hasn’t released them yet. Potential scenarios include requiring an in-person exam within 30-90 days for ongoing controlled prescribing, creating a special DEA telemedicine registration, or maintaining some level of flexibility for mental health treatment. Providers should have contingency plans — such as hybrid care models or affiliate clinic relationships for in-person visits — and stay updated through DEA alerts and professional organization communications.

References

1. DEA & HHS Telemedicine Extension Announcement (November 15, 2024) – https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. Center for Connected Health Policy – State Telehealth Policies for Online Prescribing (Updated January 9, 2026) – https://www.cchpca.org/topic/online-prescribing/

3. Florida Statutes – F.S. 456.47 (Telehealth Services) and F.S. 464.012 (Advanced Practice Registered Nurses) (2025 edition) – http://www.leg.state.fl.us/Statutes/

4. New York Department of Health – I-STOP/PDMP Program (Effective August 27, 2013) – https://health.ny.gov/professionals/narcotic/prescription_monitoring

5. Texas Board of Nursing – APRN Prescriptive Authority FAQ (Updated December 9, 2025) – https://www.bon.texas.gov/faqpracticeaprn.asp.html

Source:

• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=forward%20for%20telemedicine%2C%20DEA%20and,through%20the%20end%20of%202024
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Controlled%20Substance%20Act
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Note%20that%20the%20practice%20of,chapter%205%20of%20title%205
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,services%20within%20the%20applicable%20scope
• https://healthweb-back.health.ny.gov/professionals/narcotic/prescription_monitoring/#:~:text=Effective%20August%2027%2C%202013%2C%20most,to%20view%20dispensed%20controlled%20substance
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=may%20prescribe%20Schedule%20II%20drugs%3F,care%20from%20a%20qualified%20hospice
• https://www.leg.state.fl.us/Statutes/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=893.03%20to%20a%207,formulary%20which%20it%20finds%20is
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Additionally%2C%20the%20rule%20shall%20state,addiction%20medicine%2C%20or%20palliative%20care
• https://www.cchpca.org/topic/online-prescribing/#:~:text=The%20Attorney%20General%20may%20issue,application%20for%20such%20special%20registration%E2%80%94